|Home | About | Journals | Submit | Contact Us | Français|
Contributors: WMS designed, developed, and coordinated the study, carried out the data analysis, and interpreted the data. FDJ, the principal investigator, designed the study, and had input into development, data analysis, and interpretation. DJG designed the study and was involved throughout in study supervision and data interpretation. SG supervised the recruitment of pregnant women at the antenatal clinic, the questionnaire returns, and the recording of information by the midwives and helped with data collection. GJH designed the study and was involved throughout in study supervision and data interpretation. WMS wrote the paper jointly with FDJ, with input from the other authors. WMS and FDJ are guarantors for the paper.
The benefits of testing pregnant women for HIV are increasingly assured, particularly with regard to reducing vertical transmission.1 Yet uptake of antenatal HIV testing in Britain remains low.2 Our previous study examined an opt-in approach (women had to make an active choice to be tested).3 Some women were uncomfortable with this, feeling that it indicated high risk behaviour. We therefore assessed an approach based on similar requirements for information and consent but with a change in emphasis, in that testing was routine unless the woman declined.
The testing programme was conducted during February to April 1998. Before their booking appointment, all women were sent a leaflet about blood tests to be conducted, including HIV testing. At the antenatal clinic they were offered an HIV test by midwives who had been trained to use a printed discussion protocol that emphasised the benefits and presented the test as routine, making it clear that the woman could decline. As with the other blood tests, consent was given orally. The midwives noted uptake, time taken to discuss the test, and whether the woman or her partner was at risk of HIV from injecting drug use (this used to be the main local source of HIV transmission, although sexual transmission now predominates4). Women were then asked to complete a questionnaire measuring attitudes, satisfaction, anxiety,5 knowledge about the test, and reasons for agreeing to or declining the test. Key outcomes were compared with those observed in the same setting during 1996-7.3
Of the 924 women who booked at the clinic, 816 (88.3%) had an HIV test; one woman not at high risk was found to be HIV positive. One woman was already known to be HIV positive and was not tested. The prevalence of HIV positivity was therefore 2/817 (0.2%). The mean time taken to offer the test was 2 minutes 34 seconds (range 1-15 minutes). One of the eight women at high risk because of injecting drug use declined to be tested.
The questionnaire response rate was 99.1% (916/924). Most women (793/904 (87.7%)) answered yes to the question, “Do you think the HIV test should be a routine test like all the other blood tests during pregnancy (i.e. it’s done unless you say you don’t want it)?” The mean anxiety score was 33.2 (SD 10.6; maximum possible 80). A question about reducing vertical transmission with zidovudine elicited a correct response by 69% of women (628/905). The most frequent reasons given for declining the test were, “Not necessary as I’ve no chance of being positive” (n=28) and “I’ve been in a stable relationship for a long time” (n=15).
The uptake of the HIV test (88%) in this study is more than double the rate (35%) achieved in the 1996-7 opt-in study3 (table). During the year between the two studies, the attitude of women and midwives to HIV testing may have changed owing to increasing knowledge about effective treatment and considerable media exposure. Yet despite these possible changes, the magnitude of the increase in uptake suggests that this approach is more effective than an opt-in approach, and those who decline testing do not seem to be doing so because of high risk status. Moreover, this approach was not time consuming, required no extra staff, and was positively endorsed by most women. Compared with women in the opt-in study, the women were significantly less anxious and more knowledgeable about the protective effects of zidovudine; there was no evidence that women found it difficult to decline a est.
We cannot conclude that this approach will achieve a similar outcome in London, where there are more complex issues of language and cultural heterogeneity. But provided that safeguards are in place to ensure that women can make a fully informed choice, our routine voluntary approach is in keeping with recent guidelines1 and may be acceptable and appropriate in other clinics in high prevalence areas.
We thank especially Barbara Hamilton for the database management and clerical support. We are also grateful to the antenatal clinic midwives, the auxiliaries, the medical records staff, and the pregnant women who took the time to participate in the study.
Funding: NHS Research and Development Health Technology Assessment Programme.
Competing interests: None declared.